Infectious Bronchitis Virus

Overview and Taxonomy of Infectious Bronchitis Virus

The infectious bronchitis virus (IBV) stands as a seminal pathogen within the field of veterinary virology, not only because of its profound economic impact on global poultry production but also due to its historical significance as the first coronavirus ever to be described [3, 5]. Discovered in the 1930s, IBV was the initial member of what is now recognized as the Coronaviridae family, a lineage that includes formidable human pathogens such as SARS-CoV, MERS-CoV, and SARS-CoV-2 [5]. Taxonomically, IBV is classified within the genus Gammacoronavirus, a distinction that sets it apart from the Alpha and Betacoronavirus genera that contain most human coronaviruses [3, 5, 14]. This classification is rooted in the comparative analysis of viral genome architecture and phylogenetic relationships, highlighting the unique evolutionary trajectory of this avian pathogen.

The viral particle itself is an enveloped, pleomorphic structure approximately 80–120 nm in diameter, characterized by the iconic club-shaped spike (S) glycoprotein projections that extend from its surface, giving it a crown-like (corona) appearance under electron microscopy [1, 2]. The genome of IBV is a positive-sense, single-stranded RNA molecule of approximately 27.6 kb in length, making it one of the larger RNA virus genomes [5, 26]. This genomic RNA is packaged within a helical nucleocapsid composed of the nucleocapsid (N) protein and is surrounded by a lipid bilayer derived from the host cell membrane. Embedded within this envelope are three major structural proteins: the spike (S) glycoprotein, the membrane (M) protein, and the envelope (E) protein [5, 26]. The canonical genomic organization of IBV follows the pattern typical of coronaviruses: 5′ untranslated region (UTR) - replicase gene (ORF1a/1b) - spike (S) - accessory genes 3a, 3b - envelope (E) - membrane (M) - accessory genes 4b, 4c, 5a, 5b - nucleocapsid (N) - 3′ UTR [5, 19]. This complex architecture, particularly the presence of multiple accessory genes, underpins the virus's ability to modulate host cellular machinery and evade immune responses.

The replicase gene, occupying approximately two-thirds of the genome, is translated into two large polyproteins, pp1a and pp1ab. These are subsequently cleaved by viral proteases into 15 or 16 non-structural proteins (nsps) that form the replication-transcription complex (RTC) [5, 27]. Among these, nsp9 plays an essential role in viral RNA synthesis through its conserved homodimeric structure that binds single-stranded RNA, and its three-dimensional structure for IBV has been elucidated, confirming a conservation of the dimerization mode across all coronavirus genera [27]. Other nsps, such as nsp10 and nsp14, have been identified as key targets for rational attenuation, with specific amino acid substitutions (Pro85Leu in nsp10 and Val393Leu in nsp14) leading to a significantly attenuated phenotype both in vivo and in ovo, providing a promising avenue for the development of next-generation live vaccines [9].

For decades, the classification of IBV strains was a chaotic and often contradictory endeavor, with field isolates being designated based on geographic origin, serotype, or arbitrary naming conventions. The lack of a standardized system hindered global epidemiological surveillance and vaccine strategy development. This problem was systematically addressed by a landmark study that proposed a unified, phylogeny-based classification system for IBV [12]. This scheme, which has become the international standard, relies on the complete nucleotide sequence of the S1 subunit of the spike gene for genetic typing. The S1 gene is the most variable region of the IBV genome and encodes the receptor-binding domain (RBD), which is the primary determinant of serotype and the target of neutralizing antibodies [1, 4, 12]. The system initially defined six genotypes (GI to GVI), which were further subdivided into multiple viral lineages (e.g., GI-1, GI-13, GI-19) and inter-lineage recombinants [12]. As the understanding of IBV global diversity has expanded, this classification has been updated to incorporate additional genotypes, currently encompassing GI through GIX, each containing multiple distinct lineages [1, 8]. This genotyping framework has been critical for mapping the global spread and evolution of IBV, revealing a dynamic landscape of co-circulating strains with varying degrees of antigenic relatedness.

The molecular mechanisms driving IBV diversity are profound and continuous. As an RNA virus, IBV possesses an inherently error-prone RNA-dependent RNA polymerase (RdRp), which generates a high frequency of point mutations during replication [4, 7, 22]. This genetic drift allows the virus to rapidly adapt to selective pressures, including those imposed by the host immune system and vaccination programs. Analyses of selective pressure have consistently demonstrated that the S1 gene, particularly regions encoding hypervariable domains, is under strong positive selection, especially in the context of widespread vaccine use [16, 30]. However, the most significant driver of IBV evolution is homologous recombination [4, 7, 11, 15]. As a coronavirus, IBV generates a nested set of subgenomic mRNAs during replication, and the discontinuous transcription mechanism can lead to template switching between co-infecting viral genomes. This process is remarkably frequent; whole-genome sequencing of European field strains identified a staggering 215 recombination events across 69 genomes, with over 90% of field isolates showing evidence of recombination [11]. Recombination can occur between different field strains, between a field strain and a live attenuated vaccine strain, or even between multiple vaccine strains [11, 18, 31]. These events can rapidly shuffle genomic modules, creating chimeric viruses with novel antigenic profiles, altered tissue tropism, or increased virulence. For instance, the novel genotype GVII-1 was shown to have originated from recombination events that replaced the spike gene of a GI-18-like virus with an as-yet-unidentified sequence [17]. Similarly, the Delmarva DMV/1639 variant (GI-17) circulating in North America exhibits a mosaic genome derived from a Connecticut vaccine-like strain, a 4/91 vaccine-like strain, and an unidentified third parent [20, 23]. The propensity for recombination is so high that it has been debated whether live attenuated vaccines themselves can act as a source of new viral diversity under field conditions, potentially contributing to the emergence of vaccine-derived variants that complicate control efforts [16, 18].

The global distribution of IBV genotypes is a complex and continuously shifting picture, shaped by viral evolution, international trade of poultry and poultry products, and the selective pressure exerted by vaccination practices. A comprehensive continental analysis of IBV genotypes has elucidated the major epidemiological patterns [1]. Genotype I (GI) is the most widely distributed group, found on virtually every continent where poultry are raised, and it contains several lineages of major global significance. This includes the Massachusetts serotype (GI-1), the prototypical and historically most used vaccine strain; the 4/91 (also known as 793B) serotype (GI-13), a major cause of respiratory and reproductive disease in Europe and Asia; the QX-like strains (GI-19), which emerged in China in the 1990s and have since spread to become a dominant genotype across Eurasia and parts of Africa, often associated with nephropathogenic disease; and the GI-23 lineage (Var2-like), which originated in the Middle East and has subsequently disseminated into Europe and Asia, raising significant concern due to its ability to cause disease in vaccinated flocks [1, 10, 25, 28, 30]. Other genotypes show more restricted geographical patterns. Genotype II (GII) is predominantly a European lineage, though it has also been detected in South America, and includes the D181 serotype (GII-2), an emergent variant in layers that causes dramatic drops in egg production [1, 13]. Genotypes III (GIII) and V (GV) are largely confined to Australia, reflecting the long-standing geographical isolation of the continent's poultry industry [1, 5]. Genotypes IV (GIV), VIII (GVIII), and IX (GIX) have their origins in North America, although GIV has also been reported in Asia [1, 8]. Genotype VI (GVI) appears to be restricted to Asia, particularly China [1]. Furthermore, the continuous discovery of new genotypes, such as GI-28, GI-29, GI-30, and GVII-1 in China, underscores the relentless pace of evolution and the challenge this poses for global disease surveillance and control [8, 17, 24, 29]. In regions like Mexico, a high genetic diversity is maintained through the co-circulation of divergent lineages belonging to different genotypes, many of which are antigenically distinct from the commonly used Massachusetts and Connecticut vaccine strains, explaining why vaccination failures are a frequent occurrence [8].

The biological significance of this taxonomic diversity is immense. The spike protein S1 subunit dictates serotype specificity, and there is poor antigenic cross-protection between different genotypes and even between some lineages within the same genotype [1, 4, 6, 15]. Consequently, immunity induced by vaccination against one strain may be largely ineffective against a heterologous challenge strain. This immunological mismatch is the central obstacle in IBV control and is a primary reason why the virus remains a persistent threat to the global poultry industry, causing significant economic losses through respiratory disease, nephritis, poor weight gain, and severe drops in egg production and quality [1, 3, 7, 21]. The World Organisation for Animal Health (WOAH) recognizes infectious bronchitis as a notifiable and economically critical disease, and its control is a priority for veterinary services worldwide. The continuous emergence of antigenic variants forces the poultry industry into a perpetual cycle of developing and deploying new vaccines that better match circulating field strains, a strategy that is both costly and often only partially successful. An understanding of IBV taxonomy, therefore, is not merely an academic exercise; it is the foundational knowledge needed to interpret epidemiological patterns, predict vaccine efficacy, and design rational, region-specific control programs. The most recent comprehensive reviews confirm that despite intensive biosecurity and immunization, the introduction of novel variants continues to compromise the ability of the poultry industry to grow and prosper, making IBV a persistently dynamic and formidable pathogen [1, 4].

Molecular Pathogenesis and Virulence Mechanisms

Infectious bronchitis virus (IBV), the prototypical member of the Gammacoronavirus genus, represents a formidable pathogen whose capacity for disease stems from a sophisticated interplay of viral genetic architecture, host cell subversion, and immune evasion. The molecular pathogenesis of IBV is not a monolithic process; rather, it is a highly orchestrated sequence of events, from initial attachment and entry, through hijacking of cellular machinery for replication, to the induction of tissue-specific pathology and systemic disease. The virulence of a given IBV strain is a multifactorial trait, dictated by the precise sequence of its genome, which encodes a suite of structural, non-structural, and accessory proteins that collectively determine tropism, replication efficiency, and the ability to counteract the host's antiviral defenses [5, 32]. A nuanced understanding of these mechanisms is crucial, as it directly informs the development of rationally attenuated vaccines and therapeutic strategies, an endeavor of significant economic importance to the global poultry industry, recognized by the World Organisation for Animal Health (WOAH) as a key trade concern.

Cellular Entry and Receptor Interactions: The Determinants of Tropism

The initial step in IBV pathogenesis is the attachment of the virion to the host cell surface, a process mediated by the heavily N-glycosylated spike (S) glycoprotein. The S1 subunit, specifically its receptor-binding domain (RBD), engages the cellular receptor. For most IBV strains, the primary receptor is α-2,3-linked sialic acid, particularly N-acetylneuraminic acid (Neu5Ac) [38, 45]. This interaction is critically modulated by N-glycosylation of the spike; specific glycans on the RBD dictate the precise sialic acid linkage recognized, thereby influencing receptor specificity and, consequently, tissue tropism. Mutagenesis studies have demonstrated that removal of individual N-glycosylation sites on the RBD can shift receptor preference from Neu5Ac to other, unknown sialylated glycans, profoundly altering viral binding and infectivity [38].

Beyond sialic acid, IBV utilizes alternative or co-receptors to facilitate entry. Heat shock protein member 8 (HSPA8) has been identified as an attachment factor that interacts directly with the RBD of the S1 protein from multiple IBV strains, including M41, Beaudette, and QX. Expressed on the cell membrane, HSPA8 is particularly abundant in kidney tissue, a finding that correlates with the nephropathogenicity of certain IBV strains. Blocking this interaction with recombinant HSPA8 or specific antibodies significantly inhibits infection in vitro, establishing HSPA8 as a critical host factor in the IBV entry process [36]. Following receptor binding, IBV entry into the host cell is dependent on clathrin-mediated endocytosis and requires a low pH environment. The dynamin GTPase is essential for vesicle scission, and the virus subsequently traffics through the classical endosomal/lysosomal pathway, with Rab5 and Rab7 being necessary for productive infection [40]. The fusion of the viral and endosomal membranes is ultimately triggered by the acidic pH within the late endosome/lysosome, a process mediated by the S2 subunit after its proteolytic cleavage [40, 42]. The S2 subunit itself is a major determinant of cellular tropism; a specific region of only three amino acids surrounding the S2′ cleavage site in the Beaudette strain confers the ability to infect Vero cells, a trait not shared by the virulent M41 strain [42]. This highlights how minor sequence variations in the spike can dictate the host range and cellular permissiveness.

The Replicase Complex and Non-Structural Proteins as Virulence Factors

Once internalized and uncoated, the ~27.6 kb positive-sense RNA genome is translated to produce two large polyproteins, pp1a and pp1ab, which are co- and post-translationally processed by viral proteases into 15 to 16 non-structural proteins (nsps). These nsps assemble into the replication-transcription complex (RTC), a membrane-anchored structure that is the engine of viral RNA synthesis. The functions of many nsps have been confirmed in IBV, and their individual contributions to pathogenesis are increasingly clear [5].

Crucially, specific amino acid substitutions within nsps have been directly linked to virulence attenuation. Reverse genetics studies have pinpointed that mutations, particularly Pro85Leu in nsp10 and Val393Leu in nsp14, are sufficient to attenuate the virulent M41 strain in vivo and in ovo. Nsp10 is a cofactor for the nsp14 3′-to-5′ exoribonuclease (ExoN), which functions in proofreading during RNA replication. Nsp14 is a bifunctional protein possessing both ExoN and N7-methyltransferase (N7-MTase) activities, critical for RNA cap synthesis. The identification of these specific attenuating mutations provides a rational pathway for developing stable, live-attenuated vaccines that are unlikely to revert to virulence [9]. Furthermore, the nsp9 protein, a single-stranded RNA-binding protein, is essential for viral replication. The crystal structure of IBV nsp9 reveals a dimer formed through a hydrophobic interface, a configuration conserved among coronaviruses. Disruption of this dimerization, for instance through mutations in key residues like Phe66, Tyr69, and Leu115, abolishes RNA binding and is therefore a potential target for broad-spectrum anti-coronavirus therapy [27]. The RTC is also a hotspot for recombination, a major driver of IBV evolution. Recombination breakpoints are frequently identified within the nsp2, nsp3, nsp8, and nsp12 coding regions, and the exchange of these large genomic fragments between different field and vaccine strains can generate novel chimeric viruses with altered pathogenic potential [11, 19, 34].

Manipulation of the Host Cell: Autophagy, Apoptosis, and Immune Evasion

IBV pathogenesis is defined not only by direct viral replication but also by the manipulation of fundamental host cell processes. IBV infection induces a non-canonical autophagy pathway that is dependent on autophagy-related 5 (ATG5) but surprisingly independent of beclin 1 (BECN1). This process is regulated by the ER stress sensor inositol-requiring enzyme 1 (IRE1) and the mitogen-activated protein kinase (MAPK) ERK1/2. This virus-driven autophagy is hypothesized to facilitate the formation of the double-membrane vesicles (DMVs) that serve as the scaffold for the RTC, thereby promoting efficient viral replication [35].

Concurrently, IBV actively triggers apoptosis through both the extrinsic and intrinsic pathways to facilitate viral dissemination and exacerbate tissue pathology. Infection of chicken macrophage HD11 cells leads to the activation of caspases, notably caspase-3, -8, and -9, alongside upregulation of pro-apoptotic Bax and downregulation of anti-apoptotic Bcl-2 [44]. The c-Jun N-terminal kinase (JNK) pathway, specifically via its upstream kinase MKK7, is activated during IBV infection and serves as a key pro-apoptotic signal. Remarkably, JNK promotes apoptosis not through its canonical substrate, c-Jun, but rather by modulating the levels of the anti-apoptotic protein Bcl-2 [43]. This intricate regulation suggests that IBV finely balances the induction of apoptosis to promote viral release while ensuring sufficient time for progeny virion assembly. Antiviral compounds like hypericin and lithium chloride have been shown to mitigate IBV-induced apoptosis by dampening the expression of Fas, FasL, JNK, and caspases, and by restoring Bcl-2 levels, underscoring the centrality of apoptosis in disease pathogenesis [33, 37].

To establish a productive infection, IBV must also counteract the host innate immune response, particularly the interferon (IFN) system. The virus employs multiple strategies to achieve this. The accessory proteins, which are dispensable for replication in vitro but critical in vivo, play a significant role. Deletion of genes 3a, 3b, 5a, or 5b from the IBV genome results in an attenuated phenotype. Notably, accessory protein 5b has been implicated in delaying the activation of the host interferon response [41]. At a more specific level, IBV has been shown to inhibit the TLR7-MYD88 signaling pathway while simultaneously activating the TLR3-TIRF pathway. This selective modulation is likely to skew the immune response away from an effective antiviral state, as TLR7 is a sensor for single-stranded RNA viruses and a potent inducer of type I IFNs [39]. Furthermore, IBV infection of macrophages, while productive, suppresses the production of the antimicrobial molecule nitric oxide (NO), thereby crippling an important component of the innate bactericidal response and potentially predisposing birds to secondary bacterial infections, a common and severe complication of infectious bronchitis [21, 46]. This combination of autophagy induction, controlled apoptosis, and targeted immune suppression represents a highly effective viral strategy for ensuring robust replication and dissemination within the host.

Genetic and Antigenic Diversity of Infectious Bronchitis Virus

The genetic and antigenic diversity of Infectious Bronchitis Virus (IBV) represents perhaps the single most formidable obstacle to the sustainable and profitable production of poultry on a global scale. As a positive-sense, single-stranded RNA virus belonging to the Gammacoronavirus genus, IBV is inherently predisposed to rapid evolutionary change [1, 3, 5]. Its relatively error-prone RNA-dependent RNA polymerase (RdRp), combined with a large genome (~27.6 kb) that is highly amenable to homologous recombination, generates a staggering array of viral genotypes and serotypes [4, 7, 11]. This intrinsic plasticity allows the virus to continually evade host immune pressures, including those induced by vaccination, leading to the perpetual emergence of novel variants that challenge established control programs [6, 21, 49]. The World Organisation for Animal Health (WOAH) recognizes IB as a disease of significant socio-economic importance, and this status is directly attributable to the pathogen’s relentless diversification, which complicates both diagnosis and prophylactic intervention [22, 50].

The Molecular Engines of Diversity: Mutation and Recombination

Two principal mechanisms drive the genetic diversification of IBV: the high frequency of point mutations and the high rate of RNA recombination. The intrinsic mutation rate of coronaviruses, while partially tempered by a 3’-5’ exoribonuclease (nsp14) proofreading activity, is still sufficiently high to foster significant sequence heterogeneity, particularly within the gene encoding the spike (S) glycoprotein [7, 9]. This enzyme, nsp14, is itself a hotspot for mutations that can affect viral fitness and attenuation [9]. The spike protein, which projects from the viral envelope and mediates attachment to host cell receptors, is under intense selective pressure from the host immune system. Consequently, its S1 subunit, which contains the receptor-binding domain (RBD) and several hypervariable regions (HVRs), exhibits the greatest degree of genetic and antigenic variation across all IBV strains [12, 30, 59]. Amino acid substitutions, insertions, and deletions in the S1 gene are the primary drivers of new serotype emergence, as changes in this domain directly alter the virus’s ability to bind neutralizing antibodies [4, 47, 54]. The selective pressures exerted by vaccination programs can accelerate this process, actively driving the evolution of vaccine-escape variants, as demonstrated by increased diversifying selection on S1 residues within or near receptor attachment domains following the introduction of homologous vaccines in the field [16].

Beyond point mutation, recombination is a defining feature of IBV evolution and is arguably more consequential for the genesis of radically novel genotypes [11, 15]. Given the segmented nature of coronavirus replication, which involves a full-length negative-sense template and a discontinuous transcription strategy, the viral machinery can readily switch templates during RNA synthesis. Co-infection of a single cell with two different IBV strains, a common occurrence in high-density poultry flocks, provides the substrate for this process [18]. Recombination breakpoints are not random; analyses of whole-genome sequences have identified specific "hot spots" within the replicase genes, particularly in nsp2, nsp3, nsp8, and nsp12 [11]. However, whole-gene exchange, especially of the S gene, is a documented and potent driver of serotype change. For instance, the emergence of novel genotype GVII-1 in China resulted from a recombination event that replaced the S gene in a GI-18-like backbone with a sequence of unknown origin [17]. Similarly, the globally significant GI-19 (QX-like) lineage has been shown to participate in frequent recombination events with vaccine strains like 4/91, yielding distinct and potentially more virulent progeny [57, 60]. The Delmarva DMV/1639 variant (GI-17) isolated in North America also bears the hallmarks of recombination, with its genome comprising segments from a Connecticut vaccine-like strain, a 4/91 vaccine-like strain, and a third, unidentified parental virus [20, 23]. Such events can lead to sudden shifts in antigenicity, tissue tropism, and pathogenicity, allowing a previously obscure lineage to become dominant [5, 15].

Genotypic Classification and Global Distribution

Efforts to harmonize the chaotic nomenclature of IBV strains have led to a widely accepted phylogeny-based classification system, which, based on complete S1 gene sequences, delineates seven major genotypes (GI through GVII) comprising over 35 distinct viral lineages [1, 8, 12]. This system, initially proposed by Valastro et al. (2016), provides a standardized framework for tracking the global emergence and spread of IBV variants [12].

Genotype I (GI) is the most widespread and genetically diverse group, with its lineages circulating on every continent where poultry production occurs [1]. Within GI, several lineages have achieved particular prominence. GI-1, which includes the classic Massachusetts (Mass) serotype (e.g., M41, H120), is the historical foundation of most live-attenuated vaccines [1, 51]. GI-13, encompassing the 793B (also known as 4/91 or CR88) serotype, is highly prevalent in Europe and has demonstrated a remarkable capacity to spread globally, often becoming established in regions following vaccine introduction [1, 48, 55]. GI-19, commonly referred to as the QX-like lineage, is arguably the most economically important IBV genotype in Asia, particularly in China, where it has become the dominant circulating type since the mid-1990s [30, 47, 57]. QX-like viruses are frequently associated with severe nephropathogenic disease and proventriculitis, and they continue to diversify into distinct sublineages [14, 47, 53, 54, 56]. GI-23 (Var2-like) represents a lineage that emerged and became enzootic in the Middle East. Through continuous intra- and inter-genotypic recombination, it has since spread across Europe and Asia, causing significant outbreaks in vaccinated flocks and necessitating the development of autogenous or specific GI-23-based vaccines [1, 10, 25, 28, 34].

Other genotypes show more restricted geographic ranges. Genotype II (GII), represented initially by the D274 and D1466 strains, was considered a European genotype. The notable emergence of the GII-2 lineage (strain D181) in the Netherlands, Germany, and Belgium, which rapidly rose from obscurity to become a major isolate in layers and breeders, demonstrates the potential for even previously rare genotypes to achieve epidemic status due to a lack of cross-protection from common vaccines [13]. Genotypes III (GIII) and V (GV) are predominantly confined to Australia, reflecting the continent's long history of geographic isolation in the evolutionary trajectory of IBV [1, 5]. Genotypes IV (GIV), VIII (GVIII), and IX (GIX) are recognized as originating from North America, although GIV has also been detected in Asia [1, 8]. The diversity within a single country can be staggering. For example, surveillance in China has revealed the co-circulation of six distinct genotypes (GI-1, GI-7, GI-13, GI-19, GI-28, GI-29) alongside novel recombinants [17, 24, 29, 47, 57]. Similarly, Mexico harbors a remarkable mixture of lineages from GI, GVIII, and GIX, which are antigenically distinct from the Mass and Connecticut vaccine strains used in the region, explaining widespread vaccine failures [8]. The Food and Agriculture Organization (FAO) has highlighted the critical need for regional surveillance programs to track this complex and dynamic distribution.

Antigenic Diversity and Its Consequences for Serotype Classification

Genetic divergence in the S1 gene does not always correlate perfectly with antigenic distinctiveness, yet the emergence of new serotypes is the most direct and problematic outcome of IBV evolution. Serotype is traditionally defined by virus neutralization (VN) tests: if sera raised against one strain fails to neutralize another to a significant degree, they are considered distinct serotypes [13, 24]. For IBV, most novel genotypes identified through S1 sequencing also represent novel serotypes, meaning that infection or vaccination with one serotype offers very poor cross-protection against another [6, 21, 24]. The GI-28 and GI-29 lineages, for instance, were each confirmed as entirely novel serotypes through cross-neutralization assays, indicating that existing vaccines would be ineffective against them [24, 29].

The molecular basis for this antigenic variation resides predominantly in the S1 protein's HVRs. Exchanging these HVRs between different strains via reverse genetics can alter viral pathogenicity and tropism, but it may not be sufficient to fully convert serotype identity, suggesting that regions outside these highly variable segments also contribute to the neutralizing antibody epitope landscape [59]. Furthermore, post-translational modifications like N-linked glycosylation of the spike protein play a critical role in shaping antigenicity and receptor specificity. Specific N-glycans on the RBD of IBV-M41 are not just structural additions; they are determinants of which sialic acid receptor the virus can bind. Loss of specific glycans can switch receptor specificity from Neu5Ac to an alternative sialylated glycan, which may have profound effects on tissue tropism and the ability of antibodies to block infection [38, 58]. This interplay between genetic sequence, glycosylation, and antigenicity adds a formidable layer of complexity to predicting the emergence of new vaccine-escape variants. The selective pressure from the host's Major Histocompatibility Complex (MHC), particularly the compact chicken MHC (BF region), also plays a role. Different MHC haplotypes are associated with resistance or susceptibility to IBV, likely by influencing the repertoire of T-cell epitopes presented, thereby driving selection for variants that can evade these specific immune responses [52].

Global Epidemiology and Geographic Distribution of IBV Genotypes

The global epidemiology of Infectious Bronchitis Virus (IBV) is a dynamic and complex tapestry, shaped by the virus’s high mutation and recombination rates, intensive poultry production systems, and the relentless selective pressure exerted by vaccination programs [2, 3, 7]. As a positive-sense, single-stranded RNA virus, IBV possesses a remarkable capacity for genetic plasticity, which has resulted in the emergence of a vast array of genotypes, serotypes, and variants with distinct geographic distributions and pathogenic profiles [4, 5]. The World Organisation for Animal Health (WOAH) recognizes IBV as a pathogen of significant economic importance, and its global impact is a direct consequence of this genetic diversity, which continuously undermines control strategies [1, 50]. The establishment of a harmonized phylogeny-based classification system, utilizing the complete S1 gene sequence, has been instrumental in organizing this diversity into distinct genotypes (GI through GIX) and numerous lineages (1–35), providing a standardized framework for understanding global distribution patterns [8, 12].

Genomic Architecture and Classification of Global Lineages

The foundation of modern IBV epidemiology rests on the genetic characterization of the spike (S) glycoprotein, particularly the S1 subunit, which contains the receptor-binding domain and is the primary target for neutralizing antibodies [12, 36]. The S1 gene is a hypervariable region, subject to intense positive selection pressure, which drives the emergence of antigenically distinct variants [30]. The widely adopted Valastro et al. (2016) classification system [12] defines genotypes based on a threshold of >10% nucleotide divergence in the S1 gene, with lineages representing more closely related groups within a genotype. This system has been essential for elucidating the global distribution of IBV, revealing that Genotype I (GI) is the most geographically widespread, encompassing a diverse array of lineages such as GI-1 (Massachusetts-like), GI-13 (4/91-like), GI-19 (QX-like), and GI-23 (Var2-like), among others [1, 51]. In contrast, other genotypes exhibit more restricted or region-specific distributions, a pattern often linked to historical introductions, trade networks, and local vaccination practices. For instance, Genotype II (GII) was first identified as a European strain that subsequently disseminated to South America [1], while Genotypes III (GIII) and V (GV) are predominantly endemic to Australia, with only sporadic reports elsewhere [1, 5]. Similarly, Genotypes IV (GIV), VIII (GVIII), and IX (GIX) have their origins in North America but have since spread through trade and migratory birds [1, 8, 20].

Geographic Distribution of Major Genotypes: A Continent-by-Continent Analysis

Asia represents one of the most complex and diverse epicenters for IBV evolution. The GI-19 (QX-like) lineage is unequivocally the predominant genotype circulating across China [30, 47, 57]. Since its first detection in the mid-1990s, GI-19 has undergone substantial diversification, resulting in multiple sub-lineages and a high degree of S1 gene variation [57]. The persistent dominance of this lineage, despite intensive vaccination, underscores its remarkable fitness and ability to evade vaccine-induced immunity [14, 54, 56]. Co-circulating with GI-19 are several other lineages, including GI-1 (vaccine-like), GI-7 (TW-type), GI-13 (4/91-like), and GI-28, a novel serotype identified in southern China [29, 57]. The GI-23 lineage, originally enzootic to the Middle East, has also expanded its range westward into Asia, including China, further complicating the epidemiological landscape [1, 10]. The emergence of entirely novel genotypes, such as GVII-1 in southern China, which arose from recombination events between a GI-18-like virus and an unidentified S1 donor, highlights the region’s role as a global hotspot for IBV evolution [17].

Europe is characterized by a dynamic interplay of established and emerging genotypes. Historically, the GI-1 (Massachusetts), GI-12 (D274), and GI-13 (4/91) lineages have been prevalent, often associated with the widespread use of corresponding live-attenuated vaccines [11, 19, 31, 48]. However, the European landscape has been profoundly reshaped by the incursion of the GI-19 (QX-like) lineage, which first appeared in the late 2000s and has since become a dominant field strain in many countries [48, 63]. Perhaps most significantly, the GI-23 (Var2-like) lineage, previously restricted to the Middle East, has now been detected and established in multiple European nations, including Poland, Germany, and the Netherlands, demonstrating a clear westward expansion [10, 25, 28]. The emergence of a new GII serotype, D181 (GII-2), in the Netherlands, Belgium, and Germany, which rapidly evolved from a low-level incidental finding to a predominant strain in layers and breeders, exemplifies the continuous emergence of novel variants even in regions with intensive biosecurity [13]. Recombination events are particularly frequent in Europe, with evidence of genomic exchanges between field strains and vaccine strains (e.g., 4/91 and QX) giving rise to new recombinant clusters in Italy and Spain [11, 31]. The Polish epidemiological history from the 1980s to 2017 illustrates a clear evolutionary trajectory, where unique early Polish variants were eventually replaced by globally circulating lineages like GI-19 and GI-23 [19].

The Middle East and Africa present a scenario of high IBV genetic diversity and continuous evolution, largely driven by intensive poultry production and extensive vaccine use. The GI-23 lineage (Var2-like) is the dominant and enzootic genotype in the Middle East, including countries like Egypt, Saudi Arabia, and Israel [10, 34, 61, 62]. This lineage has continuously evolved through inter- and intra-genotypic recombination, leading to the emergence of highly pathogenic variants responsible for severe respiratory and nephropathogenic outbreaks [10, 34, 64]. In Egypt, for example, the Egyptian Variant II (belonging to GI-23) has been further subdivided into two phylogroups, highlighting the ongoing evolution within this lineage [65]. Other genotypes, including GI-1 (vaccine-like), GI-13, and GI-16, also circulate in the region, often in association with specific vaccination programs [34, 66]. The detection of the 793B genotype in Ethiopia marks the first confirmed report of variant IBV in that country, indicating a widening geographic distribution of established genotypes into previously uncharacterized regions of Africa [66].

The Americas exhibit a pattern of regional genotype dominance. In North America, the historical landscape has been shaped by the Massachusetts and Connecticut serotypes, but the emergence of the DMV/1639 strain (GI-17) on the Delmarva peninsula and its subsequent spread into Canada has been a major development [20, 23]. This strain, which has caused significant economic losses in broilers, arose through recombination events involving a Connecticut vaccine-like strain and a 4/91 vaccine-like strain, demonstrating the direct impact of vaccine use on the evolution of field viruses [20]. South America, particularly Brazil and Chile, presents a unique epidemiological picture. Genotype II (GII) is highly prevalent in South America, having originated from European introductions [1]. In Chile, the introduction of the 4/91 (GI-13) vaccine in 2015 appears to have directly influenced the genetic and antigenic characteristics of circulating field viruses, with later isolates showing a high relatedness to the vaccine strain itself [55]. The high genetic diversity in Mexico, with the co-circulation of four distinct GI lineages (GI-3, GI-9, GI-13, GI-30) and the tentative identification of new GVIII and GIX lineages, underscores the potential for novel genotype emergence in this region [8].

The Role of Recombination in Geographic Spread

Recombination is a primary evolutionary driver for IBV, frequently resulting in the exchange of genomic segments, particularly within the S1 gene and non-structural proteins (nsps) [7, 11, 31, 34]. This process can accelerate the emergence of novel genotypes that are capable of crossing geographic barriers and establishing in new regions. For instance, the GI-23 lineage in Europe likely originated from a Middle Eastern ancestor through recombination events that provided it with a genetic advantage [10, 28]. Similarly, the Canadian DMV/1639 isolates are clearly a product of recombination between multiple parental strains from different geographic origins [20]. The high frequency of recombination, identified in up to 90% of field strains in some European studies, underscores the fact that the geographic distribution of a genotype is not static; it is a fluid, evolving landscape where genomes are constantly being reshuffled [11]. This continuous genetic flux, combined with inadequate cross-protection from conventional vaccines, explains why IBV remains a persistent and formidable challenge to global poultry production, fundamentally jeopardizing the industry's capacity for sustainable growth [1, 4, 6].

Clinical Spectrum and Multisystemic Disease

Infectious bronchitis virus (IBV) is a highly contagious, acute viral pathogen of domestic fowl (Gallus gallus domesticus) that produces a remarkably complex and variable clinical picture, extending far beyond the respiratory tract for which the disease is named. The clinical spectrum of IBV infection is a direct reflection of the virus’s capacity for differential tissue tropism, which is primarily dictated by the molecular characteristics of the spike (S) glycoprotein, particularly the S1 subunit, and the permissiveness of host cell receptors such as heat shock protein member 8 (HSPA8) and alpha-2,3-linked sialic acid receptors [5, 36, 38]. While the respiratory form is the most recognized and classically described presentation, IBV is fundamentally a multisystemic pathogen. It can target the urinary tract, the reproductive tract, and, to a lesser extent, the gastrointestinal tract and immune system, leading to a triad of clinical syndromes: respiratory disease, nephritis/nephropathogenic disease, and reproductive disorders [1, 3, 6, 21]. The severity and primary manifestation of disease are influenced by a complex interplay of viral genotype (pathotype), the age and immune status of the host, breed susceptibility, environmental stressors, and the presence of secondary or concurrent infections [5, 49, 52]. This section provides an exhaustive examination of the clinical spectrum of IBV, delineating the pathogenesis and pathological hallmarks of each major disease manifestation.

Respiratory Manifestations: The Classical and Most Prevalent Syndrome

The respiratory tract is the primary portal of entry and the principal site of initial viral replication for IBV. Following aerosol or fomite exposure, the virus demonstrates a distinct tropism for the epithelial cells lining the nasal passages, trachea, bronchi, and air sacs [1, 2]. The clinical signs observed are a direct consequence of viral-induced cytopathology and the ensuing host inflammatory response. In susceptible flocks, the onset is typically acute and spreads rapidly, achieving high morbidity rates (often approaching 100%) within 24-48 hours [4, 21].

The pathognomonic clinical signs in young broilers and replacement pullets include tracheal rales, sneezing, coughing, nasal discharge, and marked depression. Infected birds are often observed huddling under heat sources, with ruffled feathers and closed eyes, indicative of systemic malaise [53, 56]. At the macroscopic level, post-mortem examination reveals a catarrhal to caseous exudate within the nasal passages, trachea, and bronchi. The tracheal mucosa appears congested and edematous, and in severe cases, caseous plugs may occlude the lumen, leading to asphyxiation [14, 21]. Microscopically, the hallmark of IBV infection is the loss of cilia (ciliostasis) and the subsequent desquamation of epithelial cells lining the respiratory tract [41]. The virus provokes a profound cellular infiltration of lymphocytes, macrophages, and heterophils into the lamina propria, contributing to the characteristic thickening and edema of the airway walls [67]. This severe damage to the mucociliary apparatus predisposes the respiratory tract to secondary bacterial infections, most commonly by Escherichia coli, Ornithobacterium rhinotracheale, and Mycoplasma gallisepticum, culminating in severe airsacculitis, pericarditis, and perihepatitis (often termed "complicated respiratory disease") which carries a significantly higher mortality and economic penalty than uncomplicated IBV infection [21, 49].

The immunological response in the respiratory tract is multi-faceted. The innate immune system recognizes viral pathogen-associated molecular patterns (PAMPs) via pattern recognition receptors (PRRs) such as TLR3 and TLR7. Intriguingly, pathogenic IBV strains have evolved strategies to subvert these defenses, including the inhibition of the TLR7-MYD88 pathway to dampen interferon responses, while leaving the TLR3-TIRF pathway active [39]. This dysregulation of the innate immune response contributes to the acute inflammation and tissue damage observed. The role of macrophages in this phase is dual; while they are critical for viral clearance, IBV can establish a productive infection within these cells, impairing their antimicrobial functions, such as nitric oxide (NO) production, thereby further compromising host defense and facilitating secondary invasion [46].

Nephropathogenic Form: The Urogenital and Renal Syndrome

A significant and economically devastating variant of IBV is the nephropathogenic form, caused by specific pathotypes such as GI-19 (QX-like) and GI-23 (Var2-like) [10, 14, 53]. These strains exhibit a heightened tropism for the renal tubular epithelium, in addition to the respiratory tract [5, 68]. While the initial respiratory signs may be mild or go unnoticed, the renal phase is often severe and can be the dominant clinical presentation [24, 54].

The clinical manifestation of nephropathogenic IBV (NIBV) is characterized by depression, ruffled feathers, polydipsia (excessive thirst), and the production of loose, watery droppings that contain a high concentration of urates (ureteral edema) [14, 53]. As the disease progresses, the kidneys become visibly swollen, pale, and mottled due to the interstitial accumulation of urates (visceral gout) [25, 68]. The ureters are often distended with urates. The pathogenesis involves direct viral replication in the tubular epithelial cells, leading to necrosis, desquamation, and severe interstitial nephritis [53]. This results in a functional impairment of the kidney, leading to an inability to excrete uric acid, which then crystallizes in the kidney parenchyma and on the surfaces of visceral organs (visceral gout) [68]. Mortality rates from nephropathogenic strains can be alarmingly high, particularly in young birds, with reports of up to 84% in specific pathogen-free (SPF) chickens infected with virulent QX-like strains [53]. The profound metabolic disturbances associated with renal failure, including alterations in purine and amino acid metabolism, are a primary driver of morbidity and mortality in these outbreaks [68]. This clinical picture is distinct from the classical respiratory form and highlights the remarkable versatility of IBV tissue tropism. The emergence and global spread of nephropathogenic genotypes like GI-19 and GI-23 represent a major challenge for the poultry industry, as these strains can cause catastrophic losses even in vaccinated flocks if the vaccine does not provide adequate homologous protection [14, 25, 61].

Reproductive Syndrome: The Impact on Egg Production and Quality

The economic impact of IBV on laying hens and breeding stock is primarily exerted through its devastating effects on the reproductive tract. The virus has a high tropism for the oviduct, particularly the magnum (site of albumen deposition) and the shell gland (uterus) [5, 21]. Infection can occur during initial exposure in pullets or as a recrudescence in adult layers.

Infection of susceptible laying flocks results in a dramatic and often precipitous drop in egg production, which can range from 10% to 70%, depending on the virulence of the strain and the stage of lay [1, 13, 21]. The loss is not only quantitative but also qualitative. Eggs produced during and after infection are frequently abnormal, exhibiting thin, soft, or misshapen shells, rough shells, and a loss of pigmentation [4, 6]. The internal quality of the egg also suffers, with a marked decrease in albumen quality (watery whites) [21]. The pathogenesis behind this lies in the direct damage to the epithelial cells of the shell gland, which are responsible for calcium deposition and cuticle formation. Furthermore, viral replication in the magnum can lead to an inflammatory response that disrupts the synthesis of ovalbumin and other thick albumen proteins [29].

A particularly insidious long-term consequence of infection in young pullets, especially those infected before reaching sexual maturity, is the development of cystic oviducts, also known as "false layers" or "layer M" syndrome [24, 29]. This condition results from permanent, irreversible damage to the developing oviduct, often by nephropathogenic strains. These birds fail to mature into productive layers and may be completely non-productive, constituting a significant economic loss for the producer. The reproductive syndrome is a stark example of how a pathogen that is primarily defined by its respiratory origin can have profound and lasting systemic consequences on an entirely different organ system, driven by the virus's S1-mediated cell tropism [5, 42].

Co-Infections and Multisystemic Synergy

The clinical spectrum of IBV is not static and is profoundly modulated by the presence of other pathogens. IBV is a well-known predisposing factor for severe respiratory disease complexes. The most significant synergistic interaction documented is with the H9N2 subtype of avian influenza virus (AIV). Experimental co-infection models have demonstrated that IBV can significantly enhance the pathogenicity of H9N2 AIV [67]. Chickens co-infected with IBV and H9N2 exhibit far more severe respiratory clinical signs, higher mortality, and more extensive pathological damage in the trachea and lungs compared to single infections. Mechanistically, this is linked to a synergistic amplification of the host's inflammatory response, characterized by a massive upregulation of pro-inflammatory cytokines, leading to cellular infiltration, edema, and severe tissue damage [67]. This synergy is bi-directional, as the secondary infection with H9N2 further exacerbates IBV-induced inflammation [67]. The highly variable clinical picture seen in the field, ranging from subclinical infection to high-mortality outbreaks, is often a consequence of the complex interplay between IBV strains, host immunity, and the microbial ecology of the farm, including co-infections with other viruses (e.g., Newcastle disease virus, infectious laryngotracheitis virus) and bacteria (e.g., E. coli) [49, 65, 66].

Host Factors and Genetic Determinants of Disease

The clinical outcome of IBV infection is not solely a function of viral strain. The genetics of the host, particularly the chicken major histocompatibility complex (MHC), plays a critical role in determining resistance or susceptibility to disease [52]. Specific MHC haplotypes have been shown to correlate with differential outcomes following IBV challenge, influencing the severity of clinical signs, the magnitude of the inflammatory response, and the capacity for viral clearance [52]. This genetic variability within a flock means that a single IBV strain can produce a spectrum of disease severity among individuals, from asymptomatic carriers to severely affected birds. Understanding these host genetic factors is paramount for breeding programs aiming to enhance inherent disease resistance and for designing effective vaccination strategies [52]. The clinical spectrum of IBV, therefore, is a product of these converging viral, host, and environmental determinants.

Diagnostic Approaches and Surveillance Methods

The accurate and timely diagnosis of Infectious Bronchitis Virus (IBV) infections, coupled with robust surveillance methods, constitutes the cornerstone of effective control and prevention strategies in the global poultry industry. The extraordinary genetic and antigenic diversity of IBV, driven by high mutation rates and frequent recombination events, presents a formidable challenge [3, 4, 7]. This inherent variability not only complicates clinical diagnosis, given the similarity of IBV-induced respiratory, renal, and reproductive signs to those of other pathogens, but also renders many diagnostic assays vulnerable to failure as emerging variants escape detection by primers or antibodies targeting conserved regions [7, 49]. Consequently, diagnostic approaches must be multifaceted, integrating classical virological techniques with advanced molecular and serological tools, all while being continuously validated against the evolving landscape of circulating strains. Surveillance, in parallel, must be systematic and globally coordinated to track the emergence, spread, and phylodynamics of IBV genotypes, thereby informing vaccination strategies and biosecurity measures [1, 12, 30].

Classical Virological and Pathological Diagnostic Methods

Historically, the diagnosis of infectious bronchitis (IB) began with the observation of clinical signs, respiratory distress (coughing, sneezing, tracheal rales), nephritis, and declines in egg production and quality, combined with gross pathological lesions such as tracheal mucus exudate, airsacculitis, and swollen, pale kidneys with urate deposition [5, 22, 53]. While suggestive, these findings are not pathognomonic, as similar presentations are caused by Newcastle disease virus (NDV), avian influenza virus (AIV), avian metapneumovirus (aMPV), and Mycoplasma species [6, 49]. Thus, laboratory confirmation has always been essential.

Virus Isolation. The gold standard for classical IBV detection has long been virus isolation (VI) in embryonated specific-pathogen-free (SPF) chicken eggs. Field samples, typically tracheal swabs, oropharyngeal swabs, or tissue homogenates from trachea, lungs, kidneys, or cecal tonsils, are inoculated into the allantoic cavity of 9- to 11-day-old embryonated eggs [22, 71]. After 48–72 hours of incubation, characteristic lesions, including stunting, curling (dwarfing), and urate deposition in the mesonephros, are observed [71]. Multiple blind passages (typically 3–5) may be required to adapt the virus and produce consistent embryo changes [71]. While VI is highly sensitive, it is labor-intensive, time-consuming, requires specialized facilities, and many field strains, particularly nephropathogenic ones, may be difficult to adapt, requiring repeated passages that can select for egg-adapted variants, potentially altering viral characteristics [5, 9, 76].

Histopathology and Immunohistochemistry. Histopathological examination of tracheal sections reveals characteristic ciliostasis, loss of cilia, epithelial cell sloughing, and infiltration of mononuclear cells [45, 53]. In the kidney, interstitial nephritis, tubular degeneration, and urate crystal deposition are hallmarks of nephropathogenic strains [53, 68]. Immunohistochemistry (IHC) using monoclonal or polyclonal antibodies against the viral nucleocapsid (N) or spike (S) protein can provide definitive evidence of viral antigen in formalin-fixed, paraffin-embedded tissues. IHC has been instrumental in demonstrating viral tropism, confirming the presence of IBV antigen in the trachea, lung, conjunctiva, caecal tonsils, kidney, and oviduct [13, 46].

Molecular Diagnostic Techniques: The Cornerstone of Modern Detection

The advent of reverse transcription-polymerase chain reaction (RT-PCR) and its real-time variant (qRT-PCR) has revolutionized IBV diagnostics, offering unparalleled sensitivity, speed, and specificity, and enabling direct genotyping from clinical samples [7, 22].

Conventional and Real-Time RT-PCR. Numerous conventional RT-PCR assays targeting conserved regions of the viral genome, most commonly the 3′ untranslated region (UTR) or the nucleocapsid (N) gene, have been developed for pan-IBV detection [7, 34, 74]. These assays are highly sensitive and can detect a broad range of genotypes. However, due to the high mutability of the virus, primer sets must be periodically re-evaluated. For instance, in silico analysis of widely used PCR primers revealed that primer sets adapted for genotype II (GII) strains like D181 are needed, as many general S1 primers may fail to detect such emerging variants [13]. Real-time RT-PCR (qRT-PCR) has largely superseded conventional PCR for routine diagnosis and research due to its ability to provide quantitative data on viral load and its faster turnaround time [61, 65]. TaqMan probe-based assays, in particular, offer enhanced specificity. The World Organisation for Animal Health (WOAH) recognizes qRT-PCR as a recommended method for IBV detection due to its high sensitivity and rapidity.

Genotyping and Sequencing. The hypervariable S1 subunit of the spike glycoprotein gene is the primary target for genetic typing and phylogenetic analysis because it contains epitopes responsible for serotype specificity and is under strong positive selection pressure [12, 15, 16, 30]. Genotyping is performed by amplifying a region of the S1 gene, followed by Sanger sequencing or, increasingly, next-generation sequencing (NGS). A harmonized phylogeny-based classification system, proposed by Valastro et al. [12], defines genotypes (GI through GIX) and lineages (e.g., GI-1, GI-13, GI-19, GI-23) based on complete S1 nucleotide sequences. This system has been widely adopted to replace the confusing coexistence of multiple, inconsistent nomenclature schemes [1, 8, 12].

Phylogenetic analysis is not merely an academic exercise; it is central to understanding the global molecular epidemiology and evolution of IBV. It has revealed the worldwide distribution of genotype I (GI), the European origin of GII, and the restriction of specific lineages like GI-1 (Massachusetts-like), GI-13 (4/91-like), GI-19 (QX-like), and GI-23 (Var2-like) to particular geographic regions, while also documenting their spread through trade and wild bird movement [1, 10, 48]. Deep sequencing allows for the identification of novel variants, recombinant viruses, and mixed infections, which are critical for understanding the real-time evolutionary dynamics of the virus [11, 57]. For example, sequencing efforts have identified the emergence of novel genotypes like GI-28 and GI-29 in China and GVII-1 from a recombination event [17, 24, 29].

Detecting Recombination. Recombination is a major driving force in IBV evolution, generating chimeric genomes with novel antigenic and pathogenic properties [11, 19, 20, 57]. The detection of recombination events requires whole-genome or large-genome-fragment sequencing, followed by bioinformatic analysis using tools like SimPlot, RDP4, or GARD. These analyses have revealed that recombination can involve vaccine strains (e.g., Massachusetts, 4/91, Connecticut) and field strains, generating new variants such as the DMV/1639 strain in North America and several recombinant clusters in Europe [11, 20, 31]. The identification of recombination hot spots, particularly in the nonstructural protein (nsp) 2, 3, and 16 coding regions, underscores the dynamic nature of the IBV genome [11, 78]. The emergence of the GI-23 lineage in Europe is a notable example of a recombinant variant that has become dominant, spreading from the Middle East to Europe and Asia [10, 25, 28].

Isothermal Amplification. As a field-deployable alternative to PCR, recombinase polymerase amplification (RPA) combined with nucleic acid lateral flow (NALF) immunoassays has been developed for IBV detection. This isothermal method amplifies the N gene at a constant temperature (38°C) in 20–40 minutes, and the results can be read by the naked eye. The RPA-NALF assay has shown excellent analytical sensitivity (10 genomic copies/reaction) and good concordance with qRT-PCR on clinical samples, making it a promising tool for rapid, on-site diagnosis [74].

Serological Diagnostic Approaches

Serology measures the host's humoral immune response to IBV infection or vaccination and is invaluable for flock-level surveillance, vaccine efficacy assessment, and epidemiological investigations.

Enzyme-Linked Immunosorbent Assay (ELISA). Commercial ELISAs, which typically use whole virus or recombinant N or S proteins as coating antigens, are the most widely used serological test [70, 72, 77]. They are rapid, high-throughput, and semi-quantitative, providing an estimate of flock antibody levels. However, commercial ELISAs often have reduced sensitivity for detecting antibodies against emerging, heterologous variant strains (e.g., GI-19, GI-23) due to antigenic diversity, and they cannot differentiate between infection and vaccination (DIVA) unless specifically designed [7].

Virus Neutralization Test (VNT). The VNT remains the gold standard for serotyping and for assessing antigenic relatedness between field isolates and vaccine strains [13, 24, 54, 55]. This test involves incubating serial dilutions of serum with a fixed dose of virus and inoculating the mixture into embryonated eggs or cell cultures to determine the neutralizing antibody titer. Cross-neutralization tests using antisera raised against reference strains can define new serotypes and evaluate the potential for cross-protection. For instance, the VNT was critical in characterizing strain D181 as a new serotype (GII-2) and demonstrating that the GI-29 genotype is antigenically distinct from all other known types [13, 24]. However, the VNT is laborious, expensive, and requires live virus and specific facilities, limiting its use to specialized laboratories.

Hemagglutination Inhibition (HI) Test. While IBV does not naturally hemagglutinate, the HI test can be performed after treatment of virions with neuraminidase or by using concentrated virus. This test is less commonly used than ELISA or VNT but can be useful for detecting antibodies against specific serotypes [66].

Antigen Detection Methods

Rapid antigen detection tests offer the potential for point-of-care diagnosis, circumventing the need for specialized equipment.

Immunochromatographic Strip (ICS) Test. A lateral flow assay using monoclonal antibodies against the S and N proteins of IBV has been developed. This ICS test demonstrated high specificity, detecting multiple genotypes, and showed a detection limit of 10^4.4 EID50. In experimental infections, the strip test results were consistent with RT-PCR, suggesting its utility as a rapid, on-farm screening tool for IBV [73].

Immunofluorescence and Immunoperoxidase Assays. Direct or indirect immunofluorescence (IFA) using fluorescently labeled antibodies can detect viral antigens in infected cell cultures or tissue sections. IFA is frequently used in research to confirm viral replication and to study the cellular localization of viral proteins [46, 69]. Immunoperoxidase staining is an alternative that uses a permanent colorimetric substrate, which can be viewed with a standard light microscope.

Advanced and Emerging Diagnostic Technologies

Nucleic Acid Sequencing Technologies. Whole-genome sequencing (WGS) using next-generation sequencing (NGS) platforms is becoming increasingly accessible and is transforming IBV surveillance. WGS provides the highest resolution for characterizing strains, identifying recombination breakpoints across the entire genome, and tracking the microevolution of the virus within and between flocks [11, 19, 23, 24]. It has been fundamental in establishing that the Polish IBV strains have a distinct genome backbone that was later replaced by other lineages [19].

RNA-Seq and Transcriptomics. High-throughput RNA sequencing (RNA-Seq) has been applied to study host-pathogen interactions, revealing the global transcriptional response of chicken cells to IBV infection. This approach has identified upregulation of immune-related genes, interferon-stimulated genes, and key signaling pathways (e.g., TLR3, MDA5, JNK) that are pivotal to the host's antiviral response [26, 32, 67, 68].

Proteomics and Metabolomics. Proteomic and metabolomic profiling, often coupled with transcriptomics (multi-omics), provides deep insights into the molecular mechanisms of pathogenesis. For example, a study using RNA-seq, GC-TOF/MS, and 16S rRNA-seq in nephropathogenic IBV-infected chickens revealed altered purine and amino acid metabolism in the kidney, correlated with changes in the gut microbiome [68].

Reverse Genetics for Rational Attenuation. While primarily a research tool, reverse genetics systems for IBV, such as those based on vaccinia virus or targeted RNA recombination, are critical for developing next-generation vaccines and for studying virulence determinants [5, 9, 75, 76]. By introducing targeted mutations (e.g., in nonstructural proteins 10 and 14, or by deleting accessory genes 3a, 3b, 5a, 5b), researchers can create rationally attenuated vaccine candidates with defined genetic markers [9, 41].

Surveillance Methods and Global Coordination

Effective surveillance is the bedrock of proactive IBV control. The International Organization for Epizootics (WOAH) lists IBV as a notifiable disease in many jurisdictions, although control measures vary. A comprehensive surveillance strategy integrates diagnostic data from multiple sources.

Spatial and Temporal Surveillance. Systematic monitoring of clinical cases and sequencing of S1 genes from field samples provides essential data on the prevalence and distribution of circulating genotypes [30, 47, 51]. Studies in Europe, China, the Middle East, and the Americas have documented the shifting dominance of genotypes over time. For example, the QX-like genotype (GI-19) has become the predominant strain in China and parts of Europe, while GI-13 (4/91-like) and GI-23 (Var2-like) are widely distributed in Europe and the Middle East [1, 10, 19, 47, 63]. In Australia, unique genotypes (GIII, GV) are prevalent [1, 5].

Targeted Surveillance in Vaccinated Flocks. Surveillance in vaccinated populations is crucial for detecting vaccine breaks and the emergence of immune-escape variants. Studies in Italy and Chile have shown that the introduction of live attenuated vaccines (e.g., 4/91) can exert selective pressure on field viruses, driving evolution and potentially leading to the emergence of new variants [16, 55]. Monitoring viral shedding post-vaccination by qRT-PCR is a sensitive indicator of vaccine efficacy and breakthrough infections [61].

Early Warning Systems. The first detection of a previously unrecorded lineage in a region, such as the GI-23 lineage in Germany in 2019, serves as a critical early warning signal [25]. Similarly, the rapid expansion of the D181 strain (GII-2) in layers and breeders in the Netherlands in 2018 was quickly identified through surveillance, highlighting the need for updated vaccines [13].

Diagnostic Challenges Due to Viral Diversity. The high genetic diversity of IBV poses a direct threat to the reliability of diagnostic assays. As isolates diverge from vaccine strains, PCR primers targeting the S1 gene or the 5' UTR may fail to anneal, leading to false negatives. This has been demonstrated for the D181 strain, where in silico analysis showed that many general S1 primers might not detect it [13]. Similarly, serological tests based on a single serotype may have poor sensitivity for detecting antibodies against heterologous strains [7]. Therefore, diagnostic methods must be continuously validated and updated to reflect the current genetic diversity, often requiring the design of genotype-specific or degenerate primers and the use of broad-spectrum antigen cocktails in ELISAs.

Integration with Biosecurity and Vaccination. Surveillance data are directly actionable. The detection of a specific genotype in a region or farm informs the selection of appropriate vaccines. For instance, the dominance of GI-23 in the Middle East necessitates the use of GI-23-based vaccines for adequate protection [10, 61]. Furthermore, surveillance data can detect the circulation of vaccine-derived viruses, which can recombine with field strains or revert to virulence, emphasizing the need for careful vaccine management [18, 55, 57].

The Role of Host Genetics in Disease Outcome and Surveillance

The chicken major histocompatibility complex (MHC) plays a crucial role in resistance or susceptibility to IBV. Certain B haplotypes are associated with differential immune responses and clinical outcomes [52]. While not a direct diagnostic tool, understanding the MHC background of a flock can inform breeding programs and vaccination strategies to mitigate disease impact. Additionally, the identification of host attachment factors like HSPA8, sialic acid receptors, and clathrin-mediated endocytosis pathways provides molecular targets for the development of novel antiviral therapeutics and may inform future surveillance of host range [36, 38, 40].

Vaccination Challenges and Control Strategies

The control of infectious bronchitis virus (IBV) represents one of the most formidable and persistent challenges in modern poultry medicine. Despite decades of intensive vaccination efforts and the deployment of biosecurity protocols, IBV continues to exact a heavy economic toll on the global poultry industry, largely due to the virus’s extraordinary capacity for genetic and antigenic evolution [1, 4, 6]. The difficulties inherent in IBV control are not merely a matter of vaccine efficacy but are deeply rooted in the fundamental virology of the virus, the ecology of its host populations, and the limitations of current intervention technologies. An exhaustive understanding of these challenges, coupled with a strategic vision for next-generation countermeasures, is essential for any meaningful progress.

The Inherent Challenge of IBV Genetic and Antigenic Plasticity

The principal obstacle to effective IBV control is the virus’s relentless genetic and antigenic diversification. As a positive-sense, single-stranded RNA virus, IBV possesses a highly error-prone RNA-dependent RNA polymerase, which drives a high frequency of point mutations [4, 7]. This mutational capacity is further compounded by a remarkably high rate of homologous RNA recombination, a hallmark of coronaviruses that occurs during discontinuous RNA synthesis [7, 11]. The spike (S) glycoprotein, particularly the S1 subunit which contains the receptor-binding domain and is the primary target for neutralizing antibodies, is under intense selective pressure. The hypervariable regions within S1 are hotspots for both mutation and recombination, leading to the perpetual emergence of novel genotypes and serotypes that exhibit variable or poor cross-protection when challenged with vaccines derived from heterologous strains [4, 12, 15]. The current classification system, which recognizes at least nine genotypes (GI-GIX) comprising numerous lineages, underscores the staggering diversity of circulating strains [1, 12]. For instance, genotype I (GI) alone is globally ubiquitous and encompasses lineages like GI-1 (Massachusetts), GI-13 (4/91), GI-19 (QX-like), and GI-23 (Var2-like), each with distinct antigenic profiles and pathogenic potential [1, 10, 48]. This genetic fluidity means that a vaccine effective against one lineage may offer negligible protection against a contemporaneous heterologous challenge, a phenomenon repeatedly documented in field outbreaks where vaccinated flocks succumb to disease caused by emerging variants [1, 4, 6, 14]. The situation is further complicated by the fact that recombination events are not limited to field strains; live attenuated vaccine strains themselves can recombine with circulating wild-type viruses or with other vaccine viruses, potentially generating novel, vaccine-derived recombinant strains with unpredictable virulence and antigenicity [11, 18, 20]. This phenomenon, termed "vaccine-driven evolution," has been demonstrated in multiple epidemiological studies, notably where the introduction of a 4/91 vaccine in Chile was associated with a shift in the circulating field virus population toward the GI-13 lineage, suggesting that vaccination can inadvertently shape the genetic landscape of IBV in a given region [16, 55].

Limitations and Paradoxical Risks of Current Vaccination Approaches

Current IBV control relies almost exclusively on a combination of live attenuated vaccines for priming young chicks and inactivated (killed) oil-emulsion vaccines for booster immunization in laying hens and breeders [3, 6, 21]. While this strategy can mitigate clinical disease and reduce economic losses when properly implemented, it is fraught with inherent limitations and, paradoxically, carries its own set of risks.

Live Attenuated Vaccines: These are typically generated by the empirical, serial passage of virulent field isolates in embryonated chicken eggs until they lose pathogenicity but retain immunogenicity [9, 64]. This traditional method is problematic for several reasons. First, the molecular basis of attenuation is often poorly defined, being the cumulative result of multiple, uncharacterized mutations across the genome. This creates a tangible risk of reversion to virulence, particularly after back-passage in the field, where the vaccine virus can replicate and accumulate compensatory mutations [9, 18, 41]. Second, the process of egg adaptation often selects for viruses that are highly lethal to the embryo itself, rendering them unsuitable for in ovo vaccination, a desired delivery route for modern broiler production [9]. Third, as discussed, these live viruses can persist in the environment and serve as a genetic reservoir for recombination with field strains, acting as a source of genomic diversity rather than a solution [11, 18]. The selective pressure exerted by mass vaccination with a homologous live vaccine can also drive the evolution of vaccine-escape variants, as the virus evolves to circumvent the immune response directed against a specific S1 serotype [16].

Inactivated Vaccines: While safer in terms of reversion, inactivated vaccines predominantly stimulate a humoral (antibody-mediated) immune response and are poor inducers of local mucosal immunity (IgA) and cell-mediated immunity (CMI), both of which are critical for protection at the portal of entry, the respiratory tract [6, 52]. Consequently, they are less effective as primary immunogens and are primarily used to boost systemic antibody levels in adult birds to protect the reproductive tract and maintain egg production. They do not effectively prevent infection or viral shedding from the upper respiratory tract [21]. The production of inactivated vaccines is also reliant on the same egg-adaptation process, limiting the speed at which new antigenic variants can be incorporated into commercially available products.

The Problem of Antigenic Mismatch: The cornerstone of vaccine failure is the antigenic mismatch between vaccine strains and circulating field strains [4, 8, 61]. The global poultry industry is dominated by a handful of "classic" vaccine strains, primarily Massachusetts (Mass)-type (e.g., H120, Ma5, M41) and, more recently, 4/91 (793B)-type strains [48, 51]. However, the predominant field strains in many regions, such as the QX-like (GI-19) strains in Asia and Europe, or the GI-23 (Var2-like) strains in the Middle East and now Europe, are genetically and antigenically distant from these traditional vaccines [10, 14, 47, 54]. Numerous challenge studies have demonstrated that vaccination with Mass-type vaccines provides inadequate protection against QX or GI-23 challenges, resulting in significant clinical signs, ciliostasis, and viral shedding [10, 54, 61]. Even where variant vaccines, such as those based on the 4/91 or GI-23 strains, are used, the rapid evolution of the virus means that these vaccines can quickly become outdated as new sub-lineages and recombinants emerge [55]. The Mexican experience, where circulating lineages (GI-3, GI-9, GI-13, GI-30) differ significantly from Mass and Connecticut vaccine strains, is a stark illustration of this global dilemma [8].

Next-Generation Vaccination and Integrated Control Strategies

Given the inadequacies of conventional vaccines, the research community has pivoted toward a multi-pronged strategy that includes the rational design of safer vaccines, the refinement of vaccination programs, the development of rapid diagnostic tools for surveillance, and an unwavering commitment to biosecurity and antiviral intervention.

Rational Vaccine Design Against Genetic Instability: The limitations of empirical attenuation have spurred the development of reverse genetics systems for IBV. These systems, typically based on targeted RNA recombination or full-length cDNA clones inserted into vaccinia virus or bacterial artificial chromosomes, allow for the precise engineering of the IBV genome [5, 9, 75, 76]. This technology enables the creation of "rationally attenuated" live vaccines where specific, defined mutations, such as deletions in accessory genes (e.g., 3a, 3b, 5a, 5b) or modifications in non-structural proteins (e.g., nsp10, nsp14), are introduced to stably attenuate the virus [9, 41]. Recombinant IBVs with deletions in accessory genes have shown an attenuated phenotype both in ovo and in vivo, and are considered promising candidates for a new generation of safer, more stable vaccines that are less prone to reversion [41]. Similarly, the identification of specific amino acids in the replicase gene that confer attenuation without compromising immunogenicity opens a pathway for the development of vaccines suitable for in ovo delivery [9].

To overcome the issue of antigenic diversity, vectored vaccines are being intensely explored. The most advanced of these utilize a replication-competent but avirulent vector, such as Newcastle disease virus (NDV) LaSota strain, to express the IBV S protein [62, 80]. These recombinant NDV (rNDV)-vectored vaccines offer several theoretical advantages: they are genetically stable, do not recombine with IBV field strains (as they are a different virus genus), can be administered via mass application (spray, drinking water), and provide bivalent protection against both IBV and NDV [62, 80]. Studies have shown that a prime-boost regimen with rNDV expressing the full-length S protein can provide significant protection against clinical disease and reduce tracheal viral shedding following IBV challenge [62]. Other vectored platforms under investigation include recombinant duck enteritis virus (rDEV) expressing IBV S, N, or S1 proteins [83]. Subunit vaccines, such as those based on the spike ectodomain or virus-like particles (VLPs) that co-display immunogenic epitopes, also represent a safe and DIVA (Differentiating Infected from Vaccinated Animals)-compatible alternative. Self-assembling protein nanoparticles (SAPNs) that present conserved B-cell epitopes from the S2 heptad repeat region, combined with flagellin as a self-adjuvant, have demonstrated the ability to reduce tracheal virus shedding and lesion scores in experimental settings [77]. Chimeric VLPs bearing antigens from both IBV and NDV have also shown promise in inducing robust humoral and cellular immunity [72]. Furthermore, recombinant S-ectodomain subunit vaccines, which include both S1 and S2, have shown improved tissue binding and superior protection compared to S1 alone, highlighting the potential contribution of S2-based immunity [82].

Improved Vaccination Programs and Surveillance: No vaccine will be effective if it is not deployed strategically. There is growing evidence that vaccination programs must be tailored to the local epidemiological situation. The use of a single vaccine strain, even if homologous to the challenge, is not always sufficient. Studies have demonstrated the superior efficacy of homologous prime-boost regimens (e.g., IB-VAR2 followed by IB-VAR2) over heterologous regimens when dealing with a GI-23 challenge [61]. However, the choice of vaccine must be guided by continuous molecular epidemiological surveillance. The high genetic diversity seen in regions like Mexico, China, and the Middle East dictates that vaccination strategies must be dynamic, incorporating new variant strains as they become dominant [8, 34, 47, 57]. The World Organisation for Animal Health (WOAH) and FAO have emphasized the need for regional surveillance networks to monitor the emergence and spread of IBV variants. The development of rapid, field-deployable diagnostic tools, such as immunochromatographic strips (ICS) for antigen detection and recombinase polymerase amplification (RPA) combined with nucleic acid lateral flow (NALF) immunoassays, is critical for enabling on-farm detection and real-time decision-making about vaccine selection and biosecurity interventions [73, 74]. These point-of-care diagnostics allow for the rapid identification of an outbreak genotype, enabling a targeted rather than a blanket vaccination response.

Biosecurity and Adjunctive Antiviral Strategies: Even the best vaccines can be overwhelmed by a high viral challenge dose or by co-infections. Strict biosecurity remains the non-negotiable foundation of any control program. This includes strict all-in/all-out management, effective cleaning and disinfection, control of fomites and personnel movement, and prevention of contact with wild birds [1, 6, 22]. The role of IBV in predisposing flocks to secondary bacterial infections and exacerbating the pathogenicity of other pathogens, such as H9N2 avian influenza virus, further underscores the importance of minimizing environmental viral load [67]. In parallel, research is exploring natural antiviral compounds as potential therapeutic or prophylactic adjuncts. Plant extracts from Mentha piperita (peppermint), Thymus vulgaris (thyme), and Hypericum perforatum (St. John's wort) have demonstrated significant anti-IBV activity in vitro and in vivo, potentially by modulating the host's innate immune response, such as upregulating type I interferon and downregulating pro-inflammatory cytokines [37, 69, 79]. Similarly, compounds like lithium chloride and astragalus polysaccharides have been shown to inhibit IBV replication and associated pathology in cell culture and embryo models [33, 81]. While not a replacement for vaccination, these agents could be integrated into feed or water during periods of high risk to bolster resistance and reduce viral shedding, thereby lowering the overall force of infection. The control of IBV is not a problem to be solved by a single technological fix but is rather a continuous strategic challenge demanding an integrated, adaptive, and scientifically rigorous approach.

References

[1] Rafique S, Jabeen Z, Pervaiz T, Rashid F, Luo S, Xie L, et al.. Avian infectious bronchitis virus (AIBV) review by continent. Frontiers in Cellular and Infection Microbiology. 2024. DOI: https://doi.org/10.3389/fcimb.2024.1325346

[2] Falchieri M, Coward V, Reid SM, Lewis T, Banyard A. Infectious bronchitis virus: an overview of the “chicken coronavirus”. Journal of Medical Microbiology. 2024. DOI: https://doi.org/10.1099/jmm.0.001828

[3] Zhao J, Zhao Y, Zhang G. Key Aspects of Coronavirus Avian Infectious Bronchitis Virus. Pathogens. 2023. DOI: https://doi.org/10.3390/pathogens12050698

[4] Abozeid HH. Global Emergence of Infectious Bronchitis Virus Variants: Evolution, Immunity, and Vaccination Challenges. Transboundary and Emerging Diseases. 2023. DOI: https://doi.org/10.1155/2023/1144924

[5] Quinteros J, Noormohammadi A, Lee S, Browning G, Diaz-Méndez A. Genomics and pathogenesis of the avian coronavirus infectious bronchitis virus. Australian Veterinary Journal. 2022. DOI: https://doi.org/10.1111/avj.13197

[6] Bhuiyan MSA, Amin Z, Rodrigues K, Saallah S, Shaarani S, Sarker S, et al.. Infectious Bronchitis Virus (Gammacoronavirus) in Poultry Farming: Vaccination, Immune Response and Measures for Mitigation. Veterinary Sciences. 2021. DOI: https://doi.org/10.3390/vetsci8110273

[7] Legnardi M, Tucciarone C, Franzo G, Cecchinato M. Infectious Bronchitis Virus Evolution, Diagnosis and Control. Veterinary Sciences. 2020. DOI: https://doi.org/10.3390/vetsci7020079

[8] Mendoza-González L, Marandino A, Panzera Y, Tomás G, Williman J, Techera C, et al.. Research Note: High genetic diversity of infectious bronchitis virus from Mexico. Poultry Science. 2022. DOI: https://doi.org/10.1016/j.psj.2022.102076

[9] Keep S, Stevenson-Leggett P, Dowgier G, Everest H, Freimanis GL, Oade MS, et al.. Identification of Amino Acids within Nonstructural Proteins 10 and 14 of the Avian Coronavirus Infectious Bronchitis Virus That Result in Attenuation In Vivo and In Ovo. Journal of Virology. 2022. DOI: https://doi.org/10.1128/jvi.02059-21

[10] Houta MH, Hassan KE, El-Sawah A, Elkady MF, Kilany WH, Ali A, et al.. The emergence, evolution and spread of infectious bronchitis virus genotype GI-23. Archives of Virology. 2021. DOI: https://doi.org/10.1007/s00705-020-04920-z

[11] Bali K, Bálint Á, Farsang A, Marton S, Nagy B, Kaszab E, et al.. Recombination Events Shape the Genomic Evolution of Infectious Bronchitis Virus in Europe. Viruses. 2021. DOI: https://doi.org/10.3390/v13040535

[12] Valastro V, Holmes EC, Britton P, Fusaro A, Jackwood M, Cattoli G, et al.. S1 gene-based phylogeny of infectious bronchitis virus: An attempt to harmonize virus classification. Infection, Genetics and Evolution. 2016. DOI: https://doi.org/10.1016/j.meegid.2016.02.015

[13] Molenaar R, Dijkman R, Wit JJD. Characterization of infectious bronchitis virus D181, a new serotype (GII-2). Avian Pathology. 2020. DOI: https://doi.org/10.1080/03079457.2020.1713987

[14] Zhang X, Deng T, Lu J, Zhao P, Chen L, Qian M, et al.. Molecular characterization of variant infectious bronchitis virus in China, 2019: Implications for control programmes. Transboundary and Emerging Diseases. 2020. DOI: https://doi.org/10.1111/tbed.13477

[15] Lin S, Chen H. Infectious Bronchitis Virus Variants: Molecular Analysis and Pathogenicity Investigation. International Journal of Molecular Sciences. 2017. DOI: https://doi.org/10.3390/ijms18102030

[16] Franzo G, Legnardi M, Tucciarone C, Drigo M, Martini M, Cecchinato M. Evolution of infectious bronchitis virus in the field after homologous vaccination introduction. Veterinary Research. 2019. DOI: https://doi.org/10.1186/s13567-019-0713-4

[17] Ma T, Xu L, Ren M, Shen J, Han Z, Sun J, et al.. Novel genotype of infectious bronchitis virus isolated in China. Veterinary Microbiology. 2019. DOI: https://doi.org/10.1016/j.vetmic.2019.01.020

[18] Guzmán M, Hidalgo H. Live Attenuated Infectious Bronchitis Virus Vaccines in Poultry: Modifying Local Viral Populations Dynamics. Animals. 2020. DOI: https://doi.org/10.3390/ani10112058

[19] Domańska-Blicharz K, Lisowska A, Sajewicz-Krukowska J. Molecular epidemiology of infectious bronchitis virus in Poland from 1980 to 2017. Infection, Genetics and Evolution. 2020. DOI: https://doi.org/10.1016/j.meegid.2020.104177

[20] Hassan MSH, Ojkić D, Coffin C, Cork S, Meer Fvd, Abdul-Careem MF. Delmarva (DMV/1639) Infectious Bronchitis Virus (IBV) Variants Isolated in Eastern Canada Show Evidence of Recombination. Viruses. 2019. DOI: https://doi.org/10.3390/v11111054

[21] Wit JJ(d, Cook JKA. Spotlight on avian pathology: infectious bronchitis virus. Avian Pathology. 2019. DOI: https://doi.org/10.1080/03079457.2019.1617400

[22] Ennaji Y, Khataby K, Ennaji M. Infectious Bronchitis Virus in Poultry: Molecular Epidemiology and Factors Leading to the Emergence and Reemergence of Novel Strains of Infectious Bronchitis Virus. Emerging and Reemerging Viral Pathogens. 2019. DOI: https://doi.org/10.1016/B978-0-12-814966-9.00003-2

[23] Goraichuk I, Kulkarni AB, Williams-Coplin D, Suarez D, Afonso C. First Complete Genome Sequence of Currently Circulating Infectious Bronchitis Virus Strain DMV/1639 of the GI-17 Lineage. Microbiology Resource Announcements. 2019. DOI: https://doi.org/10.1128/MRA.00840-19

[24] Jiang L, Zhao W, Han Z, Chen Y, Zhao Y, Sun J, et al.. Genome characterization, antigenicity and pathogenicity of a novel infectious bronchitis virus type isolated from south China. Infection, Genetics and Evolution. 2017. DOI: https://doi.org/10.1016/j.meegid.2017.08.006

[25] Fischer S, Klosterhalfen D, Kump FW, Casteel M. Research Note: First evidence of infectious bronchitis virus Middle-East GI-23 lineage (Var2-like) in Germany1. Poultry Science. 2019. DOI: https://doi.org/10.1016/j.psj.2019.10.031

[26] Dinan AM, Keep S, Bickerton E, Britton P, Firth A, Brierley I. Comparative Analysis of Gene Expression in Virulent and Attenuated Strains of Infectious Bronchitis Virus at Subcodon Resolution. Journal of Virology. 2019. DOI: https://doi.org/10.1128/JVI.00714-19

[27] Hu T, Chen C, Li H, Dou Y, Zhou M, Lu D, et al.. Structural basis for dimerization and RNA binding of avian infectious bronchitis virus nsp9. Protein Science. 2017. DOI: https://doi.org/10.1002/pro.3150

[28] Lisowska A, Sajewicz-Krukowska J, Fusaro A, Pikuła A, Domańska-Blicharz K. First characterization of a Middle-East GI-23 lineage (Var2-like) of infectious bronchitis virus in Europe. Virus Research. 2017. DOI: https://doi.org/10.1016/j.virusres.2017.09.010

[29] Chen Y, Jiang L, Zhao W, Liu L, Zhao Y, Shao Y, et al.. Identification and molecular characterization of a novel serotype infectious bronchitis virus (GI-28) in China. Veterinary Microbiology. 2016. DOI: https://doi.org/10.1016/j.vetmic.2016.12.017

[30] Zhao Y, Zhang H, Zhao J, Zhong Q, Jin J, Zhang G. Evolution of infectious bronchitis virus in China over the past two decades. Journal of General Virology. 2016. DOI: https://doi.org/10.1099/jgv.0.000464

[31] Moreno A, Franzo G, Massi P, Tosi G, Blanco Á, Antilles N, et al.. A novel variant of the infectious bronchitis virus resulting from recombination events in Italy and Spain. Avian Pathology. 2016. DOI: https://doi.org/10.1080/03079457.2016.1200011

[32] Zhang Y, Xu Z, Cao Y. Host Antiviral Responses against Avian Infectious Bronchitis Virus (IBV): Focus on Innate Immunity. Viruses. 2021. DOI: https://doi.org/10.3390/v13091698

[33] Liu X, Chang X, Wu Q, Xu J, Chen L, Shen R, et al.. Lithium chloride inhibits infectious bronchitis virus-induced apoptosis and inflammation. Microbial Pathogenesis. 2021. DOI: https://doi.org/10.1016/j.micpath.2021.105352

[34] Rohaim M, Naggar RFE, Abdelsabour MA, Mohamed MHA, El-Sabagh I, Munir M. Evolutionary Analysis of Infectious Bronchitis Virus Reveals Marked Genetic Diversity and Recombination Events. Genes. 2020. DOI: https://doi.org/10.3390/genes11060605

[35] Fung TS, Liu D. The ER stress sensor IRE1 and MAP kinase ERK modulate autophagy induction in cells infected with coronavirus infectious bronchitis virus. Virology. 2019. DOI: https://doi.org/10.1016/j.virol.2019.05.002

[36] Zhu P, Lv C, Fang C, Peng X, Sheng H, Xiao P, et al.. Heat Shock Protein Member 8 Is an Attachment Factor for Infectious Bronchitis Virus. Frontiers in Microbiology. 2020. DOI: https://doi.org/10.3389/fmicb.2020.01630

[37] Chen H, Feng R, Muhammad I, Abbas G, Zhang Y, Ren Y, et al.. Protective effects of hypericin against infectious bronchitis virus induced apoptosis and reactive oxygen species in chicken embryo kidney cells. Poultry Science. 2019. DOI: https://doi.org/10.3382/ps/pez465

[38] Bouwman KM, Habraeken N, Laconi A, Laconi A, Berends A, Groenewoud L, et al.. N-glycosylation of infectious bronchitis virus M41 spike determines receptor specificity. Journal of General Virology. 2020. DOI: https://doi.org/10.1099/jgv.0.001408

[39] Zhu J, Xu S, Li X, Wang J, Jiang Y, Hu W, et al.. Infectious bronchitis virus inhibits activation of the TLR7 pathway, but not the TLR3 pathway. Archives of Virology. 2020. DOI: https://doi.org/10.1007/s00705-020-04690-8

[40] Wang H, Yuan X, Sun Y, Mao X, Meng C, Tan L, et al.. Infectious bronchitis virus entry mainly depends on clathrin mediated endocytosis and requires classical endosomal/lysosomal system. Virology. 2018. DOI: https://doi.org/10.1016/j.virol.2018.12.012

[41] Laconi A, Beurden SJv, Berends A, Krämer-Kühl A, Jansen CA, Spekreijse D, et al.. Deletion of accessory genes 3a, 3b, 5a or 5b from avian coronavirus infectious bronchitis virus induces an attenuated phenotype both in vitro and in vivo. Journal of General Virology. 2018. DOI: https://doi.org/10.1099/jgv.0.001130

[42] Bickerton E, Maier HJ, Stevenson-Leggett P, Armesto M, Britton P. The S2 Subunit of Infectious Bronchitis Virus Beaudette Is a Determinant of Cellular Tropism. Journal of Virology. 2018. DOI: https://doi.org/10.1128/JVI.01044-18

[43] Fung TS, Liu D. Activation of the c-Jun NH2-terminal kinase pathway by coronavirus infectious bronchitis virus promotes apoptosis independently of c-Jun. Cell Death and Disease. 2017. DOI: https://doi.org/10.1038/s41419-017-0053-0

[44] Han X, Tian Y, Guan R, Gao W, Yang X, Zhou L, et al.. Infectious Bronchitis Virus Infection Induces Apoptosis during Replication in Chicken Macrophage HD11 Cells. Viruses. 2017. DOI: https://doi.org/10.3390/v9080198

[45] Zhang W, Bouwman KM, Beurden SJv, Ordoñez SR, Eijk Mv, Haagsman H, et al.. Chicken mannose binding lectin has antiviral activity towards infectious bronchitis virus. Virology. 2017. DOI: https://doi.org/10.1016/j.virol.2017.06.028

[46] Amarasinghe A, Abdul-Cader M, Nazir S, Senapathi UDS, Meer Fvd, Cork S, et al.. Infectious bronchitis corona virus establishes productive infection in avian macrophages interfering with selected antimicrobial functions. PLoS ONE. 2017. DOI: https://doi.org/10.1371/journal.pone.0181801

[47] Lian J, Wang Z, Xu Z, Chen T, Shao G, Zhang X, et al.. Distribution and molecular characterization of avian infectious bronchitis virus in southern China. Poultry Science. 2021. DOI: https://doi.org/10.1016/j.psj.2021.101169

[48] Wit JDd, Wit Md, Cook J. Infectious Bronchitis Virus Types Affecting European Countries, A Review. Avian diseases. 2021. DOI: https://doi.org/10.1637/aviandiseases-D-21-00106

[49] Bhuiyan MSA, Amin Z, Bakar AMSA, Saallah S, Yusuf NHM, Shaarani S, et al.. Factor Influences for Diagnosis and Vaccination of Avian Infectious Bronchitis Virus (Gammacoronavirus) in Chickens. Veterinary Sciences. 2021. DOI: https://doi.org/10.3390/vetsci8030047

[50] . avian infectious bronchitis virus. CABI Compendium. 2022. DOI: https://doi.org/10.1079/cabicompendium.92904

[51] Bande F, Arshad S, Omar A, Hair-Bejo M, Mahmuda A, Nair V. Global distributions and strain diversity of avian infectious bronchitis virus: a review. Animal Health Research Reviews. 2017. DOI: https://doi.org/10.1017/S1466252317000044

[52] Silva AP, Gallardo R. The Chicken MHC: Insights into Genetic Resistance, Immunity, and Inflammation Following Infectious Bronchitis Virus Infections. Vaccines. 2020. DOI: https://doi.org/10.3390/vaccines8040637

[53] Ren G, Liu F, Huang M, Li L, Shang H, Liang M, et al.. Pathogenicity of a QX-like avian infectious bronchitis virus isolated in China. Poultry Science. 2019. DOI: https://doi.org/10.3382/ps/pez568

[54] Li S, Du L, Xia J, Du J, You G, Wen Y, et al.. Antigenic and Pathogenic Characteristics of QX-Type Avian Infectious Bronchitis Virus Strains Isolated in Southwestern China. Viruses. 2019. DOI: https://doi.org/10.3390/v11121154

[55] Guzmán M, Sáenz L, Hidalgo H. Molecular and Antigenic Characterization of GI-13 and GI-16 Avian Infectious Bronchitis Virus Isolated in Chile from 2009 to 2017 Regarding 4/91 Vaccine Introduction. Animals. 2019. DOI: https://doi.org/10.3390/ani9090656

[56] Yan S, Sun Y, Huang X, Jia W, Xie D, Zhang G. Molecular characteristics and pathogenicity analysis of QX-like avian infectious bronchitis virus isolated in China in 2017 and 2018. Poultry Science. 2019. DOI: https://doi.org/10.3382/ps/pez351

[57] Xu L, Han Z, Jiang L, Sun J, Zhao Y, Liu S. Genetic diversity of avian infectious bronchitis virus in China in recent years. Infection, Genetics and Evolution. 2018. DOI: https://doi.org/10.1016/j.meegid.2018.09.018

[58] Zheng J, Yamada Y, Fung TS, Huang M, Chia R, Liu D. Identification of N-linked glycosylation sites in the spike protein and their functional impact on the replication and infectivity of coronavirus infectious bronchitis virus in cell culture. Virology. 2017. DOI: https://doi.org/10.1016/j.virol.2017.10.003

[59] Shan D, Fang S, Han Z, Ai H, Zhao W, Chen Y, et al.. Effects of hypervariable regions in spike protein on pathogenicity, tropism, and serotypes of infectious bronchitis virus. Virus Research. 2018. DOI: https://doi.org/10.1016/j.virusres.2018.04.013

[60] Xu G, Liu X, Zhao Y, Chen Y, Zhao J, Zhang G. Characterization and analysis of an infectious bronchitis virus strain isolated from southern China in 2013. Virology Journal. 2016. DOI: https://doi.org/10.1186/s12985-016-0497-3

[61] Sultan H, Ali A, Feil WKE, Bazid AI, El-Abideen MAZ, Kilany WH. Protective Efficacy of Different Live Attenuated Infectious Bronchitis Virus Vaccination Regimes Against Challenge With IBV Variant-2 Circulating in the Middle East. Frontiers in Veterinary Science. 2019. DOI: https://doi.org/10.3389/fvets.2019.00341

[62] Abozeid HH, Paldurai A, Varghese BP, Khattar S, Afifi M, Zouelfakkar S, et al.. Development of a recombinant Newcastle disease virus-vectored vaccine for infectious bronchitis virus variant strains circulating in Egypt. Veterinary Research. 2019. DOI: https://doi.org/10.1186/s13567-019-0631-5

[63] Andreopoulou M, Franzo G, Tucciarone C, Prentza Z, Koutoulis K, Cecchinato M, et al.. Molecular epidemiology of infectious bronchitis virus and avian metapneumovirus in Greece. Poultry Science. 2019. DOI: https://doi.org/10.3382/ps/pez360

[64] Ali A, Kilany WH, El-Abideen MAZ, Sayed M, Elkady MF. Safety and efficacy of attenuated classic and variant 2 infectious bronchitis virus candidate vaccines. Poultry Science. 2018. DOI: https://doi.org/10.3382/ps/pey312

[65] Naguib M, El-kady M, Lüschow D, Hassan KE, Arafa A, EL-ZANATY A, et al.. New real time and conventional RT-PCRs for updated molecular diagnosis of infectious bronchitis virus infection (IBV) in chickens in Egypt associated with frequent co-infections with avian influenza and Newcastle Disease viruses. Journal of Virological Methods. 2017. DOI: https://doi.org/10.1016/j.jviromet.2017.02.018

[66] Hutton S, Bettridge J, Christley RM, Habte T, Ganapathy K. Detection of infectious bronchitis virus 793B, avian metapneumovirus, Mycoplasma gallisepticum and Mycoplasma synoviae in poultry in Ethiopia. Tropical Animal Health and Production. 2016. DOI: https://doi.org/10.1007/s11250-016-1195-2

[67] Kong L, You R, Zhang D, Yuan Q, Xiang B, Liang J, et al.. Infectious Bronchitis Virus Infection Increases Pathogenicity of H9N2 Avian Influenza Virus by Inducing Severe Inflammatory Response. Frontiers in Veterinary Science. 2022. DOI: https://doi.org/10.3389/fvets.2021.824179

[68] Xu P, Liu P, Zhou C, Shi Y, Wu Q, Yang Y, et al.. A Multi-Omics Study of Chicken Infected by Nephropathogenic Infectious Bronchitis Virus. Viruses. 2019. DOI: https://doi.org/10.3390/v11111070

[69] Chen H, Muhammad I, Zhang Y, Ren Y, Zhang R, Huang X, et al.. Antiviral Activity Against Infectious Bronchitis Virus and Bioactive Components of Hypericum perforatum L.. Frontiers in Pharmacology. 2019. DOI: https://doi.org/10.3389/fphar.2019.01272

[70] Ma X, Bi S, Wang Y, Chi X, Hu S. Combined adjuvant effect of ginseng stem-leaf saponins and selenium on immune responses to a live bivalent vaccine of Newcastle disease virus and infectious bronchitis virus in chickens. Poultry Science. 2019. DOI: https://doi.org/10.3382/ps/pez207

[71] Bhuiyan ZA, Ali MZ, Moula MM, Giasuddin M, Khan Z. Prevalence and molecular characterization of infectious bronchitis virus isolated from chicken in Bangladesh. Veterinary World. 2019. DOI: https://doi.org/10.14202/vetworld.2019.909-915

[72] Wu X, Zhai X, Lai Y, Zuo L, Zhang Y, Mei X, et al.. Construction and Immunogenicity of Novel Chimeric Virus-Like Particles Bearing Antigens of Infectious Bronchitis Virus and Newcastle Disease Virus. Viruses. 2019. DOI: https://doi.org/10.3390/v11030254

[73] Liu I, Lin Y, Lin Y, Jian C, Cheng I, Chen H. A Novel Immunochromatographic Strip for Antigen Detection of Avian Infectious Bronchitis Virus. International Journal of Molecular Sciences. 2019. DOI: https://doi.org/10.3390/ijms20092216

[74] El-Tholoth M, Branavan M, Naveenathayalan A, Balachandran W. Recombinase polymerase amplification–nucleic acid lateral flow immunoassays for Newcastle disease virus and infectious bronchitis virus detection. Molecular Biology Reports. 2019. DOI: https://doi.org/10.1007/s11033-019-05085-y

[75] Bickerton E, Keep S, Britton P. Reverse Genetics System for the Avian Coronavirus Infectious Bronchitis Virus. Methods in molecular biology. 2017. DOI: https://doi.org/10.1007/978-1-4939-6964-7_6

[76] Beurden SJv, Berends A, Krämer-Kühl A, Spekreijse D, Chénard G, Philipp H, et al.. A reverse genetics system for avian coronavirus infectious bronchitis virus based on targeted RNA recombination. Virology Journal. 2017. DOI: https://doi.org/10.1186/s12985-017-0775-8

[77] Li J, Helal ZH, Karch CP, Mishra N, Girshick T, Garmendia A, et al.. A self-adjuvanted nanoparticle based vaccine against infectious bronchitis virus. PLoS ONE. 2018. DOI: https://doi.org/10.1371/journal.pone.0203771

[78] Zhou H, Zhang M, Tian X, Shao H, Qian K, Ye J, et al.. Identification of a novel recombinant virulent avian infectious bronchitis virus. Veterinary Microbiology. 2017. DOI: https://doi.org/10.1016/j.vetmic.2016.12.038

[79] Lelešius R, Karpovaitė A, Mickienė R, Drevinskas T, Tiso N, Ragažinskienė O, et al.. In vitro antiviral activity of fifteen plant extracts against avian infectious bronchitis virus. BMC Veterinary Research. 2019. DOI: https://doi.org/10.1186/s12917-019-1925-6

[80] Shirvani E, Paldurai A, Manoharan VK, Varghese BP, Samal S. A Recombinant Newcastle Disease Virus (NDV) Expressing S Protein of Infectious Bronchitis Virus (IBV) Protects Chickens against IBV and NDV. Scientific Reports. 2018. DOI: https://doi.org/10.1038/s41598-018-30356-2

[81] Zhang P, Liu X, Liu H, Wang W, Liu X, Li X, et al.. Astragalus polysaccharides inhibit avian infectious bronchitis virus infection by regulating viral replication. Microbial Pathogenesis. 2017. DOI: https://doi.org/10.1016/j.micpath.2017.11.026

[82] Eldemery F, Joiner K, Toro H, Santen VVv. Protection against infectious bronchitis virus by spike ectodomain subunit vaccine. Vaccine. 2017. DOI: https://doi.org/10.1016/j.vaccine.2017.09.013

[83] Li H, Wang Y, Han Z, Wang Y, Liang S, Jiang L, et al.. Recombinant duck enteritis viruses expressing major structural proteins of the infectious bronchitis virus provide protection against infectious bronchitis in chickens. Antiviral Research. 2016. DOI: https://doi.org/10.1016/j.antiviral.2016.03.003